📋 Tender Overview
Fluorescent Nano-Agents For Super-Resolution Imaging And Sensing
Real-Time Monitoring Of Ad Pathophysiologyalzheimer’S Disease (Ad) Constitutes The Most Common Form Of Age-Related Dementia, And Its Prevalence Is Expected To Increase, Given The Rising Ageing Population. To Find Effective New Treatments, We Need To Understand The Disease-Related Mechanisms And Find Ways To Monitor Them. Funded By The Marie Sklodowska-Curie Actions Programme, The Florin Project Proposes An Innovative Nanotechnology-Based Bioimaging Approach To Monitor Key Mechanisms Implicated In Ad Pathogenesis. Researchers Plan To Develop A Real-Time Device With Temperature Biosensing And Molecular Bioimaging Capacity To Detect Related Changes In Living Tissues. The Idea Is To Advance The Diagnosis Of Ad At An Early Stage And Improve The Quality Of Life Of Afflicted Individuals.
Funded Under
Marie Sklodowska-Curie Actions (Msca)
Total Cost
€ 0,00
Eu Contribution
€ 791 200,00
Coordinated By
Ita-Suomen Yliopisto
Finland
Start Date
1 November 2022
End Date
31 October 2026
Objective
Since Alzheimer disease (AD) affects up to 50% of individuals above 85, we will witness the three-fold increase in the number of patients by 2050 if no efficient therapy will be found.
The FLORIN offers non-invasive real-time monitoring of key mechanisms involved in the AD pathogenesis by avant-garde bioimaging at temporal resolution less than 1 millisecond and spatial resolution 20 - 50 nm combined with the simultaneous all-optical thermal control with 20 mK accuracy. FLORIN relies on three pillars.
(1) super-resolution optical fluctuation image scanning microscopy (SOFISM) and photon antibunching contrast enhanced super-resolved optical imaging (Q-ISM), providing accurate real-time information on fluorescent nanoparticles delivery, their organelle-specific targeting on the molecular level, and intracellular distribution with spatial resolution below 20-50 nm;
(2) frequency upconverting quantum emitters that enable convert excitation in the tissue transparency window (from 650 to 1350 nm) to fluorescence in visual spectral range;
(3) biosensing techniques capable to detect tiny changes of temperature in the living tissue with 20 mK accuracy.
With its vision for the project and beyond, FLORIN will facilitate the further development of the devices for the clinical diagnosis and treatment of AD, being fully in line with the EU Joint Programme – Neurodegenerative Disease Research and contributing to UN Sustainable Development Goal To Ensure healthy lives and promote well-being for all at all ages .
Uniting 6 well-recognized academic partners from EU and Canada, and 3 hi-tech SMEs, ATOMICUS (Germany), Adamas (USA) and Platformina (Lithuania), FLORIN action as a part of the ‘biophotonics and quantum sensing’ flow will contribute to the rise of the potential of individuals and improve their career perspectives in research and innovations within this strongly networked European and glob
